» Articles » PMID: 36960970

Fatal Case of Progressive Mpox in a Patient with AIDS-Viral Enteropathy and Malabsorption Demanding the Use of Full Parenteral ARV and Endovenous Cidofovir

Overview
Journal Infect Dis Rep
Publisher MDPI
Date 2023 Mar 24
PMID 36960970
Authors
Affiliations
Soon will be listed here.
Abstract

We report a fatal case of disseminated mpox infection that progressed over more than three months in an HIV-infected patient with acquired immunodeficiency syndrome (AIDS). Mucocutaneous, pleuropulmonary, central nervous system, and gastrointestinal involvement was documented. This course of disease resembles progressive vaccinia, a formerly reported disease caused by uncontrolled replication of smallpox vaccination orthopoxviruses in immunosuppressed patients. Severe small bowel involvement jeopardized normal oral tecovirimat and antiretroviral therapy absorption. This problem prompted the use of full parenteral antiretrovirals and endovenous cidofovir. Although a remarkable decrease in HIV viral load occurred in six days, mpox infection continued to progress, and the patient died of septic shock. This case offers new clinical insights on the presentation of severe disease in AIDS patients. Moreover, this case alerts for the need for prompt therapy initiation in patients at risk of ominous clinical progression.

Citing Articles

An Overview of Monkeypox Virus Detection in Different Clinical Samples and Analysis of Temporal Viral Load Dynamics.

Cordeiro R, Pelerito A, de Carvalho I, Lopo S, Neves R, Rocha R J Med Virol. 2024; 96(12):e70104.

PMID: 39654358 PMC: 11628931. DOI: 10.1002/jmv.70104.


The impact of immunosuppression on the mortality and hospitalization of Monkeypox: a systematic review and meta-analysis of the 2022 outbreak.

Azzam A, Khaled H, Salem H, Ahmed A, Heniedy A, Hassan H Virol J. 2024; 21(1):130.

PMID: 38840177 PMC: 11155170. DOI: 10.1186/s12985-024-02392-0.


Challenges in Managing Treatment-Resistant Mpox Complicated by Severe Superinfection.

Fortier J, Marsalisi C, Cordova E, Guo H, Verdecia J Open Forum Infect Dis. 2024; 11(4):ofae138.

PMID: 38651138 PMC: 11034949. DOI: 10.1093/ofid/ofae138.


The diagnostic dilemma for atypical presentation of progressive human Mpox.

Sahra S, Villalobos R, Scott B, Bowman D, Sassine J, Salvaggio M BMC Infect Dis. 2023; 23(1):850.

PMID: 38053027 PMC: 10696784. DOI: 10.1186/s12879-023-08852-2.

References
1.
Carrubba S, Geevarghese A, Solli E, Guttha S, Sims J, Sperber L . Novel severe oculocutaneous manifestations of human monkeypox virus infection and their historical analogues. Lancet Infect Dis. 2023; 23(5):e190-e197. PMC: 9870321. DOI: 10.1016/S1473-3099(22)00869-6. View

2.
Siegrist E, Sassine J . Antivirals With Activity Against Mpox: A Clinically Oriented Review. Clin Infect Dis. 2022; 76(1):155-164. PMC: 9825831. DOI: 10.1093/cid/ciac622. View

3.
Govind A, Lazarte S, Kitchell E, Chow J, Estelle C, Fixsen E . Severe Mpox Infections in People With Uncontrolled Human Immunodeficiency Virus. Clin Infect Dis. 2023; 76(10):1843-1846. DOI: 10.1093/cid/ciad052. View

4.
OLaughlin K, Tobolowsky F, Elmor R, Overton R, OConnor S, Damon I . Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(37):1190-1195. PMC: 9484807. DOI: 10.15585/mmwr.mm7137e1. View

5.
Kuehn B . Early Treatment Recommended for Patients With HIV and Monkeypox. JAMA. 2022; 328(22):2203. DOI: 10.1001/jama.2022.20035. View